

HCT-116: Subcutaneous colorectal cancer xenograft tumor model

➤ Subcutaneous mouse tumor models

Subcutaneously implanted tumor cells represent a convenient means to test novel potential anticancer drugs *in vivo*. A large variety of human and murine cell lines derived from both, solid tumors or leukemias, covering a wide range of tumor geno- and phenotypes, have been adapted to grow in a murine host, and thus allow testing of a compound in the appropriate tumor model.

➤ HCT-116 cells

HCT-116 cells were isolated from a patient with a colorectal carcinoma.

As routine quality controls, the cells are regularly checked for Mycoplasma contamination and authenticity (via STR DNA Typing).




Figure 1: Hematoxylin-Eosin stained paraffin section of a subcutaneous HCT-116 xenograft.

➤ Expression of oncology relevant proteins

Expression data using western blotting and immunohistochemistry are available for a selection of protein kinases. For information, please inquire!

➤ Tumor growth in vivo

HCT-116 cells harvested from tissue culture flasks are implanted into the subcutaneous space or into the mammary fat pad (subQperior) of the left flank of the mice. Resulting tumors are monitored by calipering twice weekly.

Animal weights are measured three times weekly. Animal behaviour is monitored daily. All mice are maintained in separated isolated housing at constant temperature and humidity.

Accessory services: tumor wet weight and volume measurement at necropsy, blood sampling, flow cytometry, paraffin embedding of tumor tissue, histological & pathological analysis, cytokine determination, provision of tumor tissue for target validation.




Figure 2: Tumor growth of HCT-116 cells in a subcutaneous xenograft in vivo, tumor volume, mean values +/- SEM




Figure 3: Tumor growth of NCI-H441 cells in a subQperior xenograft in vivo, tumor volume, mean values +/- SEM

➤ Study example

In the two studies shown, mice bearing subcutaneous HCT-116 xenografts were treated with VX680 or Irinotecan, the other group with vehicle only. Treatment started after randomization when tumor volumes had reached a size of approx. 200 mm³.